Century Communities To Host June Ribbon-Cutting at Running Creek in Locust, NC
CHARLOTTE, N.C., June 12, 2025 /PRNewswire/ — Century Communities, Inc.—a top 10 national homebuilder, industry leader in online home sales, and the highest-ranked homebuilder on Newsweek's list of America's Most Trustworthy Companies 2025—announced Running Creek, the Company's new community in Locust, NC, will host a ribbon-cutting ceremony with the Stanly County Chamber of Commerce on Thursday, June 26 from 11 a.m. to 1 p.m.
The Grand Opening event will include a tour of the community's new model home—featuring the beautiful Red Cedar floor plan—a showcase of move-in ready homes at Running Creek, and special savings for early homebuyers. Attendees will also have a chance to win a round of golf for two at Red Bridge Golf Club and a gift card for The Rustic at Dennis Vineyards.
Learn about pre-Grand Opening opportunities and sign up to attend the ribbon-cutting at www.CenturyCommunities.com/RunningCreekNC.
'We're proud to officially launch Running Creek as our newest community in the Charlotte area,' said Scott Herr, Charlotte Division President. 'With beautiful floor plans on generous homesites, Running Creek offers elevated country living with convenient proximity to Charlotte.'
MORE ABOUT RUNNING CREEKNow selling from the high $400s
Single-family floor plans on 0.69-acre+ lots
Spacious two-story layouts
3 to 4 bedrooms, 3 to 4 bathrooms, 2-bay garages
2,447 to 2,892 square feet
Quartz countertops, stainless-steel appliances, 42″ cabinets and more included
Cul-de-sac homesites available
Plans with studies and lofts available
Convenient access to Concord, Kannapolis, Mint Hill, and Charlotte
Close to Lake Tillery, Morrow Mountain State Park, and Uwharrie National Forest
Minutes from hotspots like downtown Locust
Location:21023 Running Creek Church DriveLocust, NC 28097704.444.0046
COMING SOON!Meadow Creek Village in LocustMinutes from Running Creek, Meadow Creek Village is anticipated to open this summer.
Learn more and join the interest list at www.CenturyCommunities.com/MeadowCreekVillageNC.
DISCOVER THE FREEDOM OF ONLINE HOMEBUYING:
Century Communities is proud to feature its industry-first online homebuying experience on all available homes in North Carolina.
How it works:
Shop homes at CenturyCommunities.com
Click 'Buy Now' on any available home
Fill out a quick Buy Online form
Electronically submit an initial earnest money deposit
Electronically sign a purchase contract via DocuSign®
Learn more about the Buy Online experience at www.CenturyCommunities.com/online-homebuying.
About Century CommunitiesCentury Communities, Inc. (NYSE: CCS) is one of the nation's largest homebuilders, an industry leader in online home sales, and one of the highest-ranked homebuilders on Newsweek's list of America's Most Trustworthy Companies 2025—consecutively awarded for a third year—and Newsweek's list of the World's Most Trustworthy Companies 2024. Through its Century Communities and Century Complete brands, Century's mission is to build attractive, high-quality homes at affordable prices to provide its valued customers with A HOME FOR EVERY DREAM®. Century is engaged in all aspects of homebuilding — including the acquisition, entitlement and development of land, along with the construction, innovative marketing and sale of quality homes designed to appeal to a wide range of homebuyers. The Company operates in 17 states and over 45 markets across the U.S., and also offers mortgage, title, insurance brokerage, and escrow services in select markets through its Inspire Home Loans, Parkway Title, IHL Home Insurance Agency, and IHL Escrow subsidiaries. To learn more about Century Communities, please visit www.centurycommunities.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
23 minutes ago
- Malaysian Reserve
DDD Investors Have the Opportunity to Lead the 3D Systems Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In 3D Systems To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in 3D System between August 13, 2024 and May 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 8, 2025 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against 3D Systems Corporation ('3D Systems' or the 'Company') (NYSE: DDD) and reminds investors of the August 12, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) 3D Systems had understated the impact of weakened customer spending on the Company's business, while overstating its resilience in challenging industry conditions; (2) in addition, the updated milestone criteria in the United Partnership would negatively impact the Company's Regenerative Medicine Program revenue; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times. On March 26, 2025, 3D Systems issued a press release announcing its financial results for the fourth quarter ('Q4') and full-year 2024. Among other items, 3D Systems reported Q4 non-GAAP earnings-per-share of –$0.19, missing consensus estimates by $0.08 per share, and sales revenue of $111 million, representing a -3.4% year-over-year decline and missing consensus estimates by $4.17 million. Further, for full-year 2024, the Company reported sales of $440.1 million, a decrease of 10% compared to the prior year, driven by 'lower hardware systems sales due to macroeconomic factors that are negatively impacting demand.' Finally, 3D systems reported a '$9 million revenue reduction in Q4 driven by a change in accounting estimates for [the Company's] Regenerative Medicine program.' The Company disclosed that '[t]his change in estimate [was] related to the now anticipated use of pre-clinical human decedent testing[,] [. . .] which led to refinement of the milestone technical criteria.' On this news, 3D Systems' stock price fell $0.57 per share, or 20.96%, to close at $2.15 per share on March 27, 2025. Then, after the market closed on May 12, 2025, 3D Systems issued a press release announcing its financial results for the first quarter ('Q1') of 2025. Among other items, 3D systems reported: revenue of $94.5 million, down 8% year-over-year and missing consensus estimates of $99.5 million; a net loss of $37 million, or $0.28 per share, more than doubling the $16 million loss reported in Q1 2024; an adjusted loss of $0.21 per share, deeper than consensus estimates of a loss of $0.14 per share; and adjusted EBITDA of a loss of $23.9 million, deepening from a $20.1 million loss in Q1 2024. The Company attributed its disappointing results, in part, to a decline in material sales, mostly due to inventory management issues in the dental portion of its Healthcare Solutions segment. 3D Systems also announced that it was withdrawing its full-year 2025 outlook, citing prolonged softness in customer capital spending and macroeconomic uncertainty. On this news, 3D Systems' stock price fell $0.68 per share, or 26.6%, to close at $1.87 per share on May 13, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding 3D Systems' conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the 3D Systems class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
Malaysian Reserve
24 minutes ago
- Malaysian Reserve
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
CRANFORD, N.J. , July 8, 2025 /PRNewswire/ — Citius Pharmaceuticals, Inc. ('Citius Pharma' or the 'Company') (Nasdaq: CTXR) today announced that it has received formal notification from The Nasdaq Stock Market LLC ('Nasdaq') indicating that for 10 consecutive trading days, from June 20, 2025 to July 3, 2025, the closing bid price of the Company's common stock was at $1.00 per share or greater, and accordingly, the Company regained compliance with Nasdaq Listing Rule 5550(a)(2). The previously scheduled Nasdaq Hearing Panel has been cancelled. Nasdaq informed the Company that Citius Pharma's securities will continue to be listed and traded on the Nasdaq Stock Market. 'We are pleased to have regained compliance with Nasdaq's minimum bid price requirement,' said Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals. 'This reflects our continued focus on bringing critical care products to patients and creating long-term value for our shareholders.' About Citius Pharmaceuticals, Inc. Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals owns 92% of Citius Oncology. For more information, please visit Forward-Looking Statements This press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma or Citius Oncology. You can identify these statements by the fact that they use words such as 'will,' 'anticipate,' 'estimate,' 'expect,' 'plan,' 'should,' and 'may' and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma and Citius Oncology, are: our ability to maintain compliance with Nasdaq's continued listing standards; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; our ability to use the latest technology to support our commercialization efforts; our need for substantial additional funds; our ability to successfully implement and maintain distribution agreements with current or other future distribution partners; potential disruptions or performance issues involving third-party logistics providers; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our SEC filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission ('SEC') filings which are available on the SEC's website at Investor Contact:Ilanit AllenVP, Corporate Communications & Investor RelationsCitius Pharmaceuticals, ext. 113 Media Contact:Greg SalsburgSTiR-communicationsGreg@ ext. 113
Malaysian Reserve
24 minutes ago
- Malaysian Reserve
$2.35 Billion by 2030: Why In Situ Hybridization Is Revolutionizing Molecular Diagnostics
DELRAY BEACH, Fla. , July 8, 2025 /PRNewswire/ — What's driving the shift to spatially resolved molecular analysis? The global in situ hybridization market, valued at USD 1.64 billion in 2025, is projected to reach USD 2.35 billion by 2030, growing at a CAGR of 7.4%. This growth is driven by the expanding role of ISH in precision medicine, laboratory-developed tests (LDTs), and spatial transcriptomics. Technological innovations—including multiplex ISH, high-sensitivity probes, and automation—are enabling more accurate, efficient, and spatially resolved gene expression analysis in both clinical and research settings. From oncology to neuroscience, ISH is paving the way for advanced diagnostics and next-generation therapeutic strategies. Download PDF Brochure: Why is ISH becoming a molecular game-changer? In Situ Hybridization methods such as FISH and RNA-ISH are increasingly used to detect patient-specific genetic markers at the single-cell level. These techniques offer greater specificity and spatial resolution than conventional assays. For instance, Molecular Instruments' HCR Pro RNA-ISH LDT (Feb 2025) now enables differentiation between psoriasis and atopic dermatitis based on biopsy-derived immunologic markers—transforming diagnostics for millions with chronic skin conditions. Key players like Precision for Medicine, Scantox, and Plus Therapeutics are leveraging ISH to support oncology, gene therapy, and neurodegenerative disease research, further embedding these tools in drug development pipelines and personalized treatment planning. What challenges does ISH solve? ISH technologies address a number of persistent issues in molecular and histopathological diagnostics: Enables precise spatial mapping of gene expression across accuracy in difficult diagnoses where IHC or sequencing alone falls shortSupports multi-target detection for robust biomarker discovery and translational research through integration of transcriptomic and proteomic analyses. For example, Roche's FDA-cleared VENTANA Kappa and Lambda Dual ISH mRNA assay (Jan 2025) enhances lymphoma subtype detection, representing a breakthrough in ISH-based molecular diagnostics. Where is adoption accelerating the fastest? While North America leads with the largest market share due to established infrastructure and funding, rapid growth is forecasted in the Asia Pacific, driven by rising cancer incidence, government funding, and diagnostic modernization. Key momentum drivers include: China, India, and Japan investing heavily in molecular pathology labs expanding ISH capabilities for cancer and infectious disease academic and CRO adoption of automated, scalable ISH platforms. Request Sample Pages : Who are the key leaders—and how are they gaining ground? The ISH market is consolidated, with 5 major players holding 60–65% of global market share: F. Hoffmann-La Roche Ltd (Switzerland): Leading in automated ISH diagnostics, including BenchMark ULTRA PLUS and FDA-cleared lymphoma probes. Danaher (US): Through Leica Biosystems, focuses on integrated automation and spatial biology (US): Dominant in ISH probes for oncology and cytogenetics under the VYSIS (US): RNAscope portfolio expansion to 70,000+ probes position it as a spatial transcriptomics Fisher Scientific (US): Offers a comprehensive suite of ISH instruments and consumables. Recent innovations include: Leica + Bio-Techne (Apr 2025): Automated RNAscope Multiomic LS for spatial + Molecular Instruments (Jan 2025): Launched HCR Pro RNA-ISH for high-sensitivity (Jan 2025): FDA-cleared B-cell ISH + Biocare (Mar 2025): NeoPATH Pro ISH system distributed in the US. What's the biggest challenge—and how do we overcome it? Despite promising advances, high costs and technical complexity remain barriers: Capital investment: ISH instruments like Ventana Benchmark Ultra cost ~$100, Multiplex probe kits and imaging services are costly, with per-slide fees reaching $113 or protocols: Require skilled personnel and careful costs: Advanced scanners such as Vectra can cost $200/hour to operate. Solutions must focus on: User-friendly automation platforms with streamlined optimization to reduce cost per initiatives to expand technical modular platforms for research and clinical users alike. What should diagnostics leaders be asking now? Not 'Is ISH useful?'—but rather: How can ISH improve our ability to detect spatial gene expression at single-cell resolution?Which multiplexing and automation technologies can scale with our diagnostics needs?Are our assays ready for regulatory validation and clinical deployment?How can we integrate transcriptomics and proteomics within one platform? Final Thought: In Spatial Precision, There Is Power. In Multiplexing, There Is Clarity. As genomics shifts toward spatial, multiplexed, and clinically actionable diagnostics, in situ hybridization is evolving from a research tool into a cornerstone of precision healthcare. It's not just about detection anymore—it's about localization, integration, and transformation of diagnostics. In the future of molecular medicine, personalization begins with precision—and ISH is leading the charge. Key Market Players: F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), Abbott (US), Bio-Techne (US), Thermo Fisher Scientific (US), Bioview (Israel), Biocare Medical (US), Agilent Technologies (US), QIAGEN (Germany), CytoTest Inc. (US), Genemed Biotechnologies (US), ZytoVision GmbH (Germany), Abnova (Taiwan) For more information, Inquire Now! Related Reports: Companion Diagnostics Market Immunohistochemistry Market Tissue Diagnostics Market Immuno Oncology Assays Market Cancer Diagnostics Market Get access to the latest updates on Top Companies in In Situ Hybridization and In Situ Hybridization Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo; View original content:
